Cloning of the cDNA for the TATA-binding protein-associated factor_{II}170 subunit of transcription factor B-TFIID reveals homology to global transcription regulators in yeast and *Drosophila*

(RNA polymerase II/(d)ATPase activity/Trithorax)

Jan A. van der Knaap*, Jan Willem Borst*, Peter C. van der Vliet*, Reiner Gentz † , and H. Th. Marc Timmers ‡

*Laboratory for Physiological Chemistry, Utrecht University, P.O. Box 80042, 3508 TA Utrecht, The Netherlands; and [†]Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850

Communicated by Phillip A. Sharp, Massachusetts Institute of Technology, Cambridge, MA, August 27, 1997 (received for review August 4, 1997)

ABSTRACT The human transcription factor B-TFIID is comprised of TATA-binding protein (TBP) in complex with one TBP-associated factor (TAF) of 170 kDa. We report the isolation of the cDNA for TAF_{II}170. By cofractionation and coprecipitation experiments, we show that the protein encoded by the cDNA encodes the TAF subunit of B-TFIID. Recombinant TAF_{II}170 has (d)ATPase activity. Inspection of its primary structure reveals a striking homology with genes of other organisms, yeast MOT1, and *Drosophila* moira, which belongs to the Trithorax group. Both homologs were isolated in genetic screens as global regulators of pol II transcription. This supports our classification of B-TFIID as a pol II transcription factor and suggests that specific TBP–TAF complexes perform distinct functions during development.

RNA synthesis in the eukaryotic nucleus is catalyzed by three distinct RNA polymerases (pol I, II, and III) and requires in each case auxiliary initiation factors. The TATA-binding protein (TBP) was first identified as the DNA-binding subunit of transcription factor (TF) IID. Subsequently, TBP was found to perform essential roles in the pol I and III systems. The combination with other proteins (TBP-associated factors, TAFs) dictates the polymerase specificity of the TBP complex (for review see ref. 1). The TFIID complex harbors more than eight TAFs ranging in size between 18 and 250 kDa, resulting in a complex of >700 kDa. In *in vitro* assays measuring TFIID activity, it was found that TAFs play an essential role in transcription activation (for review see ref. 2). Coactivator function of TAFs is underscored by observations that individual TAFs bind different sets of activation domains and that this correlates with activation domain-specific stimulation of transcription (3, 4). In addition, specific TBP-TAF subassemblies can discriminate between different core promoters (5). The exact stoichiometry of TAFs in the TFIID complex has not been established. Certain TAFs appear to be less abundant than others, and this may relate to partial dissociation of TFIID during isolation or to the existence of different TFIID complexes in the cell (6). The latter may be explained by a model that TAFs are assembled after TBP association with the promoter (1). In this respect, it is important to note that TBP does not exist as a monomer in mammalian cell extracts (7).

A comparison of TAF genes cloned from human, *Drosophila*, and yeast revealed a high degree of structural conservation (for review see ref. 2). Genetic analyses in yeast indicated that,

as expected, genes encoding TAFs are essential for viability. However, additional experiments showed that transcription activation can occur in TAF-depleted yeast cells (8, 9). In addition, analysis of pol II holoenzyme-directed transcription indicated that *in vitro* activation can occur in the absence of TAFs (10). Together, these reports indicate that TAFs are not generally required for transcription activation in yeast.

We have found that, in mammalian cell extracts, the majority of TBP is present in the pol II initiation factor B-TFIID. This factor is comprised of TBP and a protein of 170 kDa, TAF_{II}170 (11), and can support basal transcription in transcription assays measuring TFIID activity. Of interest, transcription with B-TFIID does not respond to the activators tested (7). This indicates that the B-TFIID complex is unable to establish activator contacts, which are involved in the coactivator function of TAF components of TFIID. B-TFIID binds with less stability to the TATA box, and this property may relate to its inability to commit a template for transcription, which is in contrast to TBP or TFIID (7). In addition, B-TFIID has a potent (d)ATPase activity (11). Pugh and coworkers (12) reported that a TAF of 172 kDa is part of the pol III factor TFIIIB and proposed that it is equivalent to the TAF_{II}170 component of B-TFIID. However, other groups did not observe a TAF of 170 kDa in TFIIIB (13, 14). In addition, analysis of B-TFIID indicated that it does not function in pol III transcription assays (15). Nevertheless, it remains possible that TAF_{II}170 is present in both B-TFIID and TFIIIB factors.

In this study, we report the cloning of the $TAF_{II}170$ cDNA and its copurification with B-TFIID. In addition, we show that recombinant TAF_{II}170 protein associates with recombinant TBP and has considerable (d)ATPase activity. The primary structure of human TAF_{II}170 identifies two global regulators of pol II transcription as homologs in other organisms, which supports the role of B-TFIID as a pol II factor.

MATERIALS AND METHODS

Cloning of TAF_{II}**170 cDNA.** The EST clone encoded amino acids 1616-1699 of TAF_{II}170 and was used to screen a human B cell cDNA library following standard procedures (16). Positive clones were sequenced on both strands using the T7 sequencing kit (Pharmacia). The two longest clones (N5D and 3N10) contained a nonspliced intron. This was corrected by

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

^{© 1997} by The National Academy of Sciences 0027-8424/97/9411827-6\$2.00/0 PNAS is available online at http://www.pnas.org.

Abbreviations: TBP, TATA-binding protein; TAF, TBP-associated factor; pol, RNA polymerase; TF, transcription factor; β -ME, β -mercaptoethanol.

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AJ001017).

[‡]To whom reprint requests should be addressed. é-mail: h.t.m.timmers@med.ruu.nl.

reverse transcriptase-PCR using HeLa cell mRNA. The PCR fragment was rebuilt into the 3N10 clone after sequence verification. This cDNA lacks the first 16 codons. A mouse fibroblast cDNA library (#1023, CLONTECH) was screened with a 360-bp fragment encoding amino acids 17–153. This resulted in one positive clone, M5A, which was sequenced and used to isolate a human genomic fragment carrying the ATG and the missing codons. The genomic and cDNA sequences of human TAF_{II}170 were combined, and the DNA sequence of the human TAF_{II}170 coding and untranslated regions has been deposited in the GenBank database under accession number AJ001017.

Purification of B-TFIID and Recombinant TAF_{II}170. Protein fractions containing B-TFIID [B] or TFIID [D] were obtained by phosphocellulose chromatography of HeLa whole cell extract as described (7). B-TFIID was purified by phosphocellulose, Q-Sepharose, and MonoS chromatographic steps essentially as described (11). Subsequently, B-TFIID fractions were adjusted to buffer H [10% (vol/vol) glycerol/50 mM KCl/50 µM CaCl₂/0.5 mM phenylmethylsulfonyl fluoride/0.5 mM DTT/0.2 mM sodium bisulfite/1 µg/ml aprotinin/1 µg/ml leupeptin] plus 10 mM potassium phosphate (pH 7.0) and applied to a 5-ml hydroxylapatite column (Bio-Rad). The column was developed with a linear gradient from 10 to 250 mM potassium phosphate (pH 7.0). B-TFIID-containing fractions (140-200 mM potassium phosphate) were dialyzed to buffer A [20 mM Hepes·KOH, pH 7.9/20% (vol/vol) glycerol/1 mM EDTA/DTT/protease inhibitors as above] plus 0.1 M KCl and applied to a 1-ml heparin HiTrap column (Pharmacia). After washing with buffer A plus 0.2 M KCl, B-TFIID was step-eluted with buffer A plus 0.45 M KCl. This B-TFIID fraction was analyzed by gel filtration as described (7).

Recombinant TAF_{II}170 vaccinia viruses were generated as described earlier (17) by homologous recombination with pTAF-gptATA carrying the TAF_{II}170 ORF, in which amino acids 1-16 were replaced by MGSSHHHHHHSSGLVPRG-SHMAMGYPYDVPDYARSNS, which contains an 6x His tag to facilitate purification. For purification of recombinant TAF_{II}170, Hela S3 cells (2.5·10⁸) were infected as described (17) with TAF_{II}170 virus at a multiplicity of infection of 3 plaque forming units per cell. After a 20-h infection at 37°C, cells were harvested. A whole cell extract was prepared and adjusted to buffer T [20 mM Tris·HCl, pH 7.9/20% (vol/vol) glycerol/0.5 mM phenylmethylsulfonyl fluoride/0.2 mM sodium bisulfite] plus 50 mM KCl/1 mM EDTA/1 mM DTT. The extract was applied to a 65-ml Q-Sepharose FF column, and, after washing with buffer T plus 0.15 M KCl/0.1 mM EDTA/1 mM β -mercaptoethanol (β -ME), TAF_{II}170 protein was eluted with buffer T plus 0.45 M KCl/0.1 mM EDTA/1 mM β -ME. Imidazole was added to 1 mM, and this fraction was applied to a 2.5-ml NiNTA agarose column (Qiagen, Chatsworth, CA). The column was washed with buffer T plus 20 mM imidazole/50 mM KCl/0.1 mM EDTA/1 mM β -ME, and TAF_{II}170 protein was eluted with buffer T plus 0.25 M imidazole/50 mM KCl/0.1 mM EDTA/1 mM β-ME. TAF_{II}170 fractions were adjusted to the conductivity of buffer A plus 0.1 M KCl and applied to a 1-ml heparin HiTrap column. The column was developed by a linear gradient of 0.1-0.6 M KCl in buffer A. Recombinant TAF_{II}170 elutes at 0.28 M KCl. TAF_{II}170-containing fractions were identified by immunoblotting.

Immunological Analyses. Polyclonal antisera were raised against an N-terminal region (17–154) or against a C-terminal region (1616–1699) of human TAF_{II}170 as described (7). mAb 20C7 and 22D1 are directed against the N-terminal half of human TBP and were isolated according to standard procedures (18). For coimmunoprecipitation, protein fractions were incubated in ELB buffer [50 mM Hepes·KOH, pH 7.9/0.3 M KCl/5 mM MgCl₂/0.5 mM EDTA/0.1% Nonidet P-40/1 mM β -ME and protease inhibitors as above] with antibody-coated

protein A-agarose beads for 3 h at 4°C. The beads were washed, and immune complexes were analyzed on immunoblots, which were prepared and developed as described (18).

Coinfection by Recombinant TBP and TAF_{II}170 Vaccinia Viruses. For the coimmunoprecipitation experiment, A14 mouse fibroblast cells were infected by recombinant TAF_{II}170 and/or recombinant TBP viruses at a multiplicity of infection of 3 (TAF) or 1 (TBP) plaque forming units per cell. After 20 h of infection at 37°C, cells were washed twice with PBS and lysed by incubation in ELB buffer for 30 min at 0°C. After removal of cell debris by centrifugation, lysates were used directly.

For the NiNTA–agarose affinity step, HeLa-TK⁻ cells were infected with virus(es), and lysates were prepared as above in ELB buffer plus 1 mM imidazole and without EDTA. Lysates were applied to 1-ml NiNTA–agarose columns. After washing with ELB buffer plus 20 mM imidazole and without EDTA, bound proteins were eluted by increasing the imidazole concentration to 0.25 M in ELB buffer.

ATPase Assay. ATPase activity was measured in reactions of 10 μ l, which contained 40 mM Hepes·KOH, pH 8.05/2–4% (vol/vol) glycerol/25–35 mM KCl/0.2 mM EDTA/5 mM MgCl₂/2 mM DTT/0.5 mM phenylmethylsulfonyl fluoride/ 0.2 mg/ml BSA and were started by the addition of 100 μ M [α -³²P] ATP. After a 2-h incubation at 30°C, part of the reaction was analyzed by thin layer chromatography on poly-ethyleneimine plates using 0.5 M LiCl/1 M HCOOH as eluens. Identity of the products was verified by UV shadowing of cochromatographed ATP and ADP.

RESULTS

Generation and Analysis of TAF_{II}170 Antibodies. Microsequencing of TAF_{II}170 protein is hampered by its low abundance in mammalian extracts (11). To circumvent this, we speculated that TAF_{II}170 belongs to the SNF2 superfamily (19). This was based on its size and its apparent (d)ATPase activity (11). In addition, a member of this group, yeast Mot1p, was identified as a TAF by Weil and coworkers (20). Antisera against human members of the SNF2 family (ERCC-6, Etl-1, and an EST with homology to Mot1p) were obtained and tested for recognition of TAF_{II}170 in immunoblot experiments with B-TFIID fractions. One of these sera recognized a protein band with the mobility of TAF_{II}170. This serum was raised against an human EST clone with homology to a C-terminal region of yeast Mot1p (1612-1691). If the protein recognized by this antiserum is indeed TAF_{II}170, it should be immunoprecipitated from B-TFIID fractions by antibodies directed to TBP. This was investigated using [B] or [D] fractions from the phosphocellulose chromatographic step, which separates B-TFIID (in [B]) from traditional (D-)TFIID (in [D]) (7). Precipitated proteins were analyzed for TBP and TAF_{II}170 content by immunoblot analysis. Fig. 1A shows that the protein recognized by the antiserum is very efficiently precipitated by TBP antibodies but not by control antibodies (lanes 3 and 4). As expected, no protein bands are recognized in the anti-TBP precipitate of the (D-)TFIID fraction (Fig. 1A, lane 7). This indicates that the EST clone used to generate the antibodies is part of the human cDNA for the TAF_{II}170 protein and prompted us to isolate the remainder of the cDNA (see below).

The sequence of the EST clone is in a conserved region of the SNF2 superfamily. This raised the possibility that the antiserum was directed against another SNF2 family member but that it cross-reacted with TAF_{II}170. Therefore, we generated antibodies against the most N-terminal region of one of the obtained cDNA clones. This region is not conserved in the SNF2 superfamily. The obtained antibodies were analyzed in a TBP coprecipitation experiment. This analysis showed that the protein recognized by the N-terminal antibodies is indeed immunoprecipitated efficiently by TBP antibodies from the



FIG. 1. TAF_{II}170 is recognized by antisera raised against N- or C-terminal regions of the protein encoded by the isolated cDNA. (A)Immunoprecipitations using isolated B-TFIID or D-TFIID fractions were performed without antibody (lanes 2 and 6), with TBP mAb 22D1 (lanes 3 and 7), or with 12CA5 antibody (lanes 4 and 8) attached to protein A-agarose beads. Lanes 1 and 5 contain 50% of the input [B] or [D] fraction. Immune complexes were analyzed on immunoblots with polyclonal antibodies raised against the C terminus of TAFII170 (Upper) and, subsequently, with the TBP mAb 20C7 (Lower). The arrows indicate the positions of TAF_{II}170 and TBP. Positions of the markers (in kilodaltons) are indicated to the left. (B) The N-terminal antibodies also recognize TAF_{II}170 in B-TFIID. [B] fraction was subjected to immunoprecipitation as in A. Lane 1 contains 30% of the input [B] fraction. No antibodies (lane 2), 22D1 (lane 3) or 12CA5 antibodies (lane 4) were coupled to protein A-agarose before incubation with [B]. Immunoblots were analyzed as in A. (C). TAFII170 protein coelutes with TBP on a gel filtration column. Four microliters of the load (lane 1) and 80 μ l of fractions 8–16 (lanes 2–10) were analyzed on immunoblots with TAFII170 (Upper) and TBP antibodies (Lower) as indicated to the right. The arrows above the blot denote fractionation of standard proteins by their molecular mass.

B-TFIID fraction (Fig. 1*B*, lane 3). In a similar analysis with (D-)TFIID, this antiserum did not recognize coprecipitating proteins (data not shown).

To elaborate these findings, we analyzed fractions from the different steps of a B-TFIID purification with TAF_{II}170 and TBP antibodies. A strict coelution of TBP and TAF_{II}170 was observed (data not shown). B-TFIID peak fractions from the fifth chromatographic step were subjected to gel filtration analysis. As expected, immunoblotting analysis showed that TAF_{II}170 and TBP coelute from this column (Fig. 1*C*). Both proteins peak in fractions 10 to 12, which correspond to a molecular size of 300 kDa. This is very similar to the earlier analysis of B-TFIID (7) and illustrates the stability of the

TBP–TAF_{II}170 interaction. Taken together, the immunoblotting experiments of Fig. 1 show that cDNA sequences used to generate the antibodies encode the human TAF_{II}170 component of B-TFIID.

Analysis of the cDNA for Human TAF_{II}170. We obtained the complete ORF of human TAF_{II}170, which encodes a 1849amino acid protein with a calculated molecular mass of 206,771 Da. Whereas previous analysis indicated that the TAF component of B-TFIID has a relative mobility of 170 kDa (hence its name), TAF_{II}170 migrated closer to its calculated molecular weight in our current gel system. To avoid confusion, we will continue to refer to the TAF subunit of human B-TFIID as TAF_{II}170. As expected, the TAF_{II}170 sequence harbors the seven motifs characteristic for proteins containing ATPase activity (Fig. 2). A database search with the TAF_{II}170 ATPase region (amino acids 1263-1779) revealed 62% identity with yeast Mot1p (21) and 69% identity with Drosophila 89B helicase (22). In addition, this region is very similar to the ATPase regions of, for example, human ERCC-6, murine Etl-1, Drosophila brahma, and yeast Snf2p/Swi2p (37, 34, 35, and 33% identities, respectively).

The homology among TAF_{II}170, Mot1p, and 89B helicase extends beyond the ATPase region (Fig. 2). The first 1262 amino acids of TAF_{II}170 are 26% identical to the corresponding region of Mot1p and 33% identical to amino acids 1–343 of 89B helicase [the N-terminal half of 89B helicase has not been cloned yet (22)]. Comparison of this TAF_{II}170 region with other SNF2 family members reveals no significant homology. In conclusion, this analysis shows that TAF_{II}170, Mot1p, and 89B helicase are encoded by homologous genes in different organisms. The *Drosophila* FlyBase web site (http://morgan.harvard.edu/htbin-post/gene.script?FBgn0002783) shows that the 89B helicase is encoded by the Trithorax gene moira (23).

Association of Recombinant TAF_{II}170 with Recombinant TBP. To investigate whether the recombinant TAF_{II}170 can associate with TBP, we used the recombinant vaccinia virus system. The N terminus of TAF_{II}170 was modified by addition of a His-tag and recombinant TAF_{II}170 virus was generated. Mouse fibroblast cells were infected by this virus in combination with a TBP-expressing virus (kind gift of H. Stunnenberg). Extracts were prepared by mild lysis of the cells and subjected to immunoprecipitation with TBP antibodies. The results show that the TAF_{II} 170 protein is present in the immunoprecipitates only when cells are infected by both viruses (Fig. 3A Upper, lane 6). When cells are infected by a single virus, no TAF_{II}170 protein can be detected (Fig. 3A Upper, lanes 4 and 5). Reprobing the blot with TBP antibodies indicated that immune complexes contain recombinant TBP as expected (Fig. 3A Lower, lanes 4-6). Also, recombinant TAF_{II}170 and TBP were present in the lysates before immunoprecipitation (Fig. 3A, lanes 1-3).

To verify that recombinant TBP associates with TAF_{II}170, another approach was required because the polyclonal TAF_{II}170 antisera are not functional in immunoprecipitation. The presence of a His-tag in recombinant TAF_{II}170 facilitates affinity purification. Lysates were prepared from infected HeLa cells and subjected to NiNTA affinity chromatography. Immunoblot analysis of the fractions showed that TBP is only present in the elution step of double-infected lysates (Fig. 3B Upper, lane 12). Part of the TBP is present in flow-through and wash fractions of the column (Fig. 3B Upper, lanes 2, 3, 10, and 11). This may indicate inefficient binding of recombinant TAF_{II}170 to the column (Fig. 3B Lower, lanes 6 and 7) or that not all of the TBP is complexed with TAF_{II} 170. In the absence of recombinant TAF_{II}170, TBP has a low affinity for NiNTA (Fig. 3A Upper, lane 3). In conclusion, these experiments show that recombinant TAF_{II}170 can associate with recombinant TBP and verify that the isolated cDNA indeed encodes the TAF component of B-TFIID.

h TAF 170	NA VSRLDRLFILLDTOTTPVTRKAAAQQLGEVVKLHPHELNNLLSKVLIYLRSANWDTRIAAGQAVEAIVKNVPEWNPVPROROEDTSESSMEDSPTTERLNP	103
MOT 1	MESRVSRLDROVLLIETGGSGOVTRIMAADOMGDLARONFEDILSLLSROVPPIDVKRMERVTAARAVGGIVAHAPSMDENESDLVGGNEGSPLDDAQVKLEHE	105
mTAF 170	NA VSRLDRLFILLDTOTTPVTRKAAAQQLGEVVKLHPHELNNLLSKVLIYLRSTNWDTRIAAGQAVEAIVKNVPEWNPVPROROEDVGGNEGSPLDDAQVKLEHE	102
ЬТАГ 170 МОТ 1 МТАГ 170	DR FDICR LLONG-ASLLOSAGA EFEVQ DEX SGEV DFKERIAR ORKILOKKLG-UN-KOEAIG-KSTEELFN DEDLDYTETSAS-FVNKO-PTLOAAELIDS KIKLEEATONNO UNLGOEDHHLSSISDWRLNDIL-KSOKVLLASSMNDYN LGKAD DHIRKQAKT DDIKOYTSMANNASOKAN ENKSNAN KKSAR HLAMAR DR FDICR LLONG-ASLLOSAGAEFR VO DEK SGEV DFKERIAR ORKLLOKKLG-UN-KGEAIG-MSTEELFN DEDLDYTFTSAA-LVNKO-STLOAAELIDS 	200 205 197
ЬТА Г 170	NA GM SNR OND A MR MAKLFAKORS RDAVE - TNEKSMOST DOE PEKKRRKIANVVIN OSIND STVLIDNIPD SSSLIKETNE OPLESFCE FOND MPN SMOV	301
Нот1	NA - KKRSANSTPN MPVDITESSVSKTLLNOKNMTNSAASLATSPTSNOLNPKLE HTEONDE SKLHHESTVR PLLEONE VAGLV OOFOUT SLUIDNEMSEN WI	309
h та г 170 мот 1	REGA TELET TELET LEA HORSGERNEDS ELET 100 NOE WEEDD VIR DE VENDER FOD VIS DE VVN PVNER CAGELGVVER MNERGVH NTVDVELKULTOB 0 - REOMALOLRELVER HATGVSRVKEN REENNLENSES BEDDAS RLET VFALDER GOVVEVD VAD VRESVAGELAALDI HED SOLSI SI SI FICE OGVLOD FLOTG	402 414
h TAF 170	WEVRIGGID GOIR GALAVRODVINT MORNULTRIIEGIO DIDDOWRAVATAS DVGVVESLUV GOTOKVPFIINGLIDA GLEHDO-LTAGTNGID MES	499
Mot 1	LPNKINGATUGGIDGIR GEVSIKTNFLFAHGIDEN VVRIVLYODNOS DDOVOS VAASILTGITSEFYK GNNSTIEILVTGI SLÖAR HODDISS SVOSILDDOAK	519
h TAF 170	Ы L ТҮР ОЙО ОС SIQ O GL T VIV ЭР V W PEIH MT HSEVINTAD BET MET LOGTONO NESSIDIPILPDHLÄHI DOF CV DESSOEI DO U IH KÜM MEM SKASÜ	596
Mot 1	ОС DH Q E ÜL DI LKN KALEHPSEW SFKSIVIX LYPDIR MS ISSVINTAVIN LÖI AF DSIK DO STKNMDN G KVF ÜL V (ON IL DEO NPEL DO MS PO V V A MEH V KU	621
ЬТАГ170	Q Y V X A AC PWN GANLC LHN GIS - HIP I DANN LLE VRARAKEK I G G VR QG QGONXE VL Q Y I AG ADT HIBD PATR DF VVHRARNN AA KLLGAL CCC DCD G V NWY	700
Нот1	RHTEKT L DH V FSKHLGD I BHD MIT PV OEGGKN YAN ES QYLLKP - SOH YQLH PBK KRS GST II T DSDI PI FKN NEHINID A PMIAGD HILGLD DI	715
htaf 170	T Q EIK PAESLG QÖL ÜFHLNSKSAL QRISVAMVI ÖZMAAL QKECKA VTLAVQ PRLLDINSEÜL YYDZIA V PFTRM QN – ECKOUI SSLADVH IZ VGNR VNNN VÖTI	803
Not 1	LNTRIMGAKAFAMT MSMF Q DSTLQ SFFTNV MVR GLELFFSTPRHLAGII VSOFCSSWMQ KMPEGEKLPSFVSEIFS PVN NGOLN - RDEFPVFREL VPSLKAMRT	819
htaf 170	DQASD ZVATUFNEATSSEDD-NEQVIQ QLQALQALDSKR QQQQMTVTATNQ - GMQVLQLRVH TFAAC VVSZQQLEEKLNEI KELNEI KELMET	902
Hot 1	QCQSLZA MEDDYGMLEQYKEF UVAI VVQGETEA GENAFGVETAGKVYGZYYDKMEKSMNNSYKLLAKKEBEDSKHRVLNA M SAKUSA ULTOSILANYNS - SH	922
bTAF170	KUDQQCGTRTPCDNSKUTXNGCSGLCV-DPYGTPCGTCPGDQCCGENSKGSTSEKDGMHHTVTKGRGIILLGRHGKAGFAITSRRGP-TPKAVGAQIGDLPAG	1004
MOT1	- DGFGGLGLKLNP IIRSEMDGVKEENNEKDQTNAGESGVHHI-QGLLENNKVNVSGKIVKNLCGFLGVDTSEVPDGSVMAEVAGATTILGE-SNSHAAQ	1019
89B hel.	KUDDIFFGARVMGLETGKQTPVS-SGVINGGVYGILGGALQOTVTTTNTRRCGRCNNSGGYGGPG-GPWATATCG-IIGSAHAFA	91
hTAF170	SSGNILVELDE ΛΟΚ ΡΥLVORR GAR FAUTTIVKH GOGENAVK HEN GMU A GVORGANTIDINN FOGG 5000 - ΟΝΟΟ ΟΝΥΝΕΙΟΥΝΕΟΥΝΕΟΥΝΕ	1105
MOT1	DINLAKN SE SAQLKR GOLITOKIGTEVLOP SELOKLED GARD OF SKILED SUSDHEN BEASKVDN E GGOKIVOS FOND KALFEFNSD SUSSENS	1111
89B hel.	A HEAKEA GAN DECKION LOAA CAIEKOCKIGGE OF IEL VAV FOHLKEGKVE GFVK BA-YDWRLGED DEGVCN BAVSEN OLIGOAAA PHLHVA	188
ЬТАГ170	Q H DPH D'YN C DY DISTAVRHNAAR CY OVN SKIAT MET D'N IFLEXY DEW LGAUD SYK Q E GAIEALA CYM EQ D YG IV FYINL UVY FYL GRUSD (7 D SYRF MAT QOF	1210
МОТ1	IR FPY DL TFDR SND SY FRYSAAR TFADDAR ISSY BY DY TIR EI DEDWNSAOS D SDR Q GITE LEY HLSLSMET DYD FYY FLLWY SD SM	1216
898 hel.	AL DPS DG FIY CHPH KAVRHNAARCH AV LADE DA C QRHOFYYH DL DFLLOK HEQ DIE HQ GAIEAIE RWY SR DO IK VY FYINL UVY FLLGAM SD PD ESYRL BOTH GF	293
htaf 170	A D LIN DUPLEAGID DP DNN SAELI QLEAKERH PHEGHL DGUKLENYKI DVP IN AELRKYQOD GVNN DA PHNKYK HIG ILCD DNGLGKTLOSIC ILAGDHGHRAQE	1315
Moti	As IIX DUPLEAGIAD PHOL PERLYAS RERD PHOQUM DEGKAR PRLPIAHKAHGKKYQOD GVNN DA PHNKYH LHG ILCD DNGLGKTLOSIC ILAGDH	1321
89B hel.	Am DVQ DNPLDG KTEQLE – SD PHOARKI KOREED YHFN NYS IPNYKV DVPISVELRCYQOASIN WWALAFLNKYH LHG ILCD DNGLGKTLOSIC ILAGHHHR – Q	394
hTAF170 MOT1 89B hel.	YARSKËLECHPLESLUVCPPELTOHHVDEVICKECSR-EYËNDELHTOPËR TIRËQHÖV-KRHNILIVASYDVVRNDEDËR NËKËNYOHDESCHVFKNOKTKESK YEKTSVESRALPSLILCEPELTOHNU KUTOVEKELDOTAPEKVVVYACEPTVRLTERPOL-SDADILVASYDVARNDEAVLNKTEYNYOVDECHIKNISQIKËLAK TÅNËANDSLVICPPLTOHNU KUTEVEKELDOCSVËRËLDOGSVËR DIH VËFDVERELGEKCHLVASYDFVRRDIDES EN ENVOVDECHIKNISQIKËLAK TÅNËANIDSLVICPPLTOHNU KUTEVEKELDOCSVËR DIH VËFDVERELGEKCHLVASYDFVRRDIDES EN ENVOVDECHIKNISKI SK	1418 1422 494
hTAF170 MOT1 89B hel.	AV NO DEANVELIL SCEPIONNVLELWSLEDFLUPGELGTEROFAARYGKPILASRDARSSEREQEAGVLAMDALHEQVLEFLLERMKEDVLOLLPEKTIQDYYG AV KEICAN HELILGCEFIONNVLELWSLEDFLUPGFLGTERMED ERFAKFIAASRDARGSSKEQEAGVLAMDALHEQVLEFLERMKEDVLG AFKELGAN HELILGCEFIONNVLELWSLEDFLUPGFLGTEKOFVQRESRPIG9ERDAKSSAKEQEAGVLAMEALHEQVLEFLURVKEDVLKDLEFFITQDYYGE III	1523 1527 599
hTAF170 MOT1 89B hel.	LSPLOVOLYEDFAKSRAKCDÜDETYSSATLSFEGEK PKEKÄTGHVEQALQYERKLCNHPALVEFOHPETKITAEKÄÄVONSEHÖTONAPKESALKÖLÜLDCOL Lödlongelynderkko-knvverköten	1628 1623 701
hтаг170 мот1 8.9в hel.	GNGTSEGG-TESVVAGHRILIFCOLKSNLDIVEHDLLKPHLEBSVTYLRLEGSTEPGGRHSEVSRENNDFSIDVLLEFHVGGLGENLTGADTVUFVER GEEDIDKKAGODNFFINVEGGRAALIFCOLKDNIDNVENDLEGKYPSVTYNRLEGSIDBRDRGKVVRKENEDFSIDGLLTTKVGGLGENLTGADTVIFVEH GVOTESVSGHRALIFCOLKANLDIVEGDLBRHLEPSVTYLRLEGSVPASGRODEVNNPNSDFSIDVLLLTTWVGGLGENLTGADTVIFVEH V	1726 1728 792
bTAF170 HOT1 89B bel.	DWN PERDLOANDRAHRIGORD VN VYR LITROFLEERINGLOKFRNN IANT VLSOENSSLOSMOË DOLLDLET LDKDCKMERADIT-STGRAS DWN PENDLOANDRAHRIGORK VN VYR LITROFLEERINGLOKFRNN IANT VLSOENSSLOSMOË HOLLDLET DPDN VIS ODN-BENN HODSOA KOMEN DNN PENDLOANDRAHRIGORK VN VYR LITROSLEERINGLOKFRILLANT VVSADNASLOTMOTSOIFDLEN SCKDRGAESGSS-AV OOTANGO, VI VI	1010 1832 886
hTAF170 MOT1 89Bhel.	(1936) БАЛБИКО О ЙИДО БОТОБ БЕТКЕК ИНИ И ИЛА- L так АДХА ДО 2 ИА БЕТКИ И О БОТ 2 ХХИ И В ОТАТ- - МК (ДИТЕЙТАЦИ) В ОХ 2 ХХИ И В ОТАТ ХХИ И А - МК (ДИТЕЙТАЦИ) В ОХ 2 ХХИ ХХИ ОХ 2 ХХИ	1849 1867 920

FIG. 2. Amino acid sequence of $TAF_{II}170$ and its alignment with Mot1p and 89B helicase sequences. Alignment was performed using the CLUSTAL w algorithm (25). Only the N-terminal 205 amino acids of mouse $TAF_{II}170$ have been determined, and this part is included in the comparison. The sequence for *Drosophila* 89B helicase is derived from a partial cDNA clone, lacking the N-terminal half of the ORF. Immunoblotting experiments indicate that the full length 89B helicase protein has a molecular mass 210 kDa (22), which is similar to that of TAF_{II}170. The boxed regions mark ATPase motifs and are indicated by roman numerals. Putative nuclear localization signals are indicated by bars. The asterisk denotes the *mot1–24* mutation R1507K (30).

Analysis of (d)ATPase Activity of Recombinant TAF_{II}170. It has been shown that B-TFIID can hydrolyze both ATP and dATP (11). To test this for recombinant TAF_{II}170, we purified the protein by a combination of ion exchange and affinity chromatography. After the NiNTA affinity step, no endogenous TBP was present in the TAF_{II}170 fractions (data not shown and see also Fig. 3B Upper). Peak fractions were further purified and subsequently tested for presence of recombinant TAF_{II}170 and for ATP hydrolysis. Fig. 4 A and B show that fractions 22 and 23 contain the TAF_{II}170 peak and have the highest ATPase activity. Further analysis of fraction 23 indicated that the K_m for ATP ranges between 30 and 50 μ M (data not shown). The reaction is dependent on Mg ions and can utilize dATP. These biochemical properties of recombinant TAF_{II}170 are very similar to those of \hat{B} -TFIID (11). However, recent findings in the yeast system show stimulation of Mot1p's ATPase activity by TBP (24). To investigate this for the human system, a direct comparison of TAF_{II}170 and B-TFIID is required.

DISCUSSION

In this paper, we describe the isolation of the cDNA for $TAF_{II}170$. In a variety of assays, it is shown that the protein

encoded by this cDNA is the TAF subunit of B-TFIID. The ability to hydrolyze (d)ATP is conferred to B-TFIID by the TAF_{II}170 subunit as indicated by biochemical analysis of recombinant TAF_{II}170. Of interest, the human TAF_{II}170 gene has homologs in other organisms, the yeast MOT1 and *Drosophila* moira genes. These genes have been identified as global regulators of pol II transcription (21, 23) because mutations in these genes can affect transcription of a particular gene both positively and negatively. The relationship of TAF_{II}170 with global regulators of pol II in other organisms strongly argues against previous suggestions that the TAF component of B-TFIID is involved in the pol III transcription system (12).

The yeast MOT1 gene was initially isolated as a repressor of basal pol II transcription by two independent screens (21, 28). Recent studies indicated that Mot1p can also stimulate pol II transcription from certain genes (27, 29, 30). The MOT1 gene is essential for yeast viability, which also is observed for other TAF genes (8, 9). These findings classify Mot1p as a global regulator of pol II transcription. A model for its biochemical action is provided by the finding of Hahn and coworkers (26) that Mot1p is identical to ADI (ATP-dependent inhibitor of TBP binding). Mot1p/ADI can remove TBP from the TATA



FIG. 3. Recombinant TAF_{II}170 and recombinant TBP associate after coexpression. (A) TAF_{II}170 protein is precipitated by TBP antibodies only in the presence of recombinant TBP. A14 mouse fibroblast cells were infected with recombinant vaccinia viruses expressing TBP (lanes 1 and 4), TAF_{II}170 (lanes 2 and 5), or TBP and TAF_{II}170 (lanes 3 and 6) as indicated above the lanes. Cell lysates were subjected to immunoprecipitation by the TBP antibody 22D1. Immune complexes were washed and analyzed in lanes 4-6 on immunoblots with TBP or TAF_{II}170 antibodies as indicated. Lanes 1-3 contain 20% of the input. Arrows and molecular size markers as in Fig. 1A. (B)Recombinant TBP coelutes with recombinant His-tagged TAF_{II}170 during NiNTA affinity chromatography. Lysates of HeLa TK- cells infected with viruses expressing TBP (lanes 1-4), TAF_{II}170 (lanes 5-8), or TBP and TAF_{II}170 (lanes 9-12) were subjected to NiNTAagarose chromatography. Fractions were analyzed on immunoblots using TAF_{II}170 or TBP antibodies as indicated to the right. Load fractions were analyzed in lanes 1, 5, and 9; flow-through fractions in lanes 2, 6, and 10; wash fractions in lanes 3, 7, and 11; and elution fractions in lanes 4, 8, and 12. The asterisk indicates the heavy chain of the mouse 22D1 antibody.

box depending on ATP-hydrolysis, and this suggests that Mot1p redistributes TBP among different promoters. It was proposed that the increased mobility of TBP favors weak TATA boxes, explaining the stimulatory effect of Mot1p on TATA-less promoters (27, 30). In addition, part of the total Mot1p in yeast extracts exists in a complex with TBP (20), and it was shown very recently that the N-terminal 1281 amino acids of Mot1p are essential for TBP binding (24). In vitro transcription experiments analyzing repression by Leu3p indicated that Mot1p/TBP-containing fractions but not recombinant TBP support Leu3p repression (31). However, it is unclear if the other TAFs present in the assay are important for the corepression, and the molecular mechanism has not been determined yet. Preliminary experiments indicate that expression of human TAF_{II}170 does not suppress mot1-1 or mot1-1033 mutant alleles (H.Th.M.T. and M. A. Collart, unpublished results).



FIG. 4. Recombinant TAF_{II}170 contains ATPase activity. (*A*) Immunoblot analysis of recombinant TAF_{II}170. Fractions of the heparin affinity step were analyzed on immunoblots using TAF_{II}170 antibodies as in Fig. 1*B*. Lane 1 contains 5 μ l of the load, and lanes 2 and 3 contain 15 μ l of the flow-through and wash fractions. Lanes 4–23 contain 3 μ l of the fractions as indicated above. Arrows and molecular size markers are as in Fig. 1*A*. (*B*) ATPase activity assay of heparin fractions containing TAF_{II}170 protein. Two microliters of the load (lane 1) or flow-through (lane 2) and 1 μ l of heparin fraction 17–27 (lanes 3–13) were analyzed for ATPase activity. Positions of ATP and ADP are indicated by arrows.

The TAF_{II}170 homolog in Drosophila melanogaster is the 89B helicase protein (22), which is encoded by the moira gene. Immunological analysis indicated that the gene encodes a protein of ≈210 kDa and showed a widespread expression during development. Of interest, in the latter part of embryogenesis, the protein accumulates in the ventral nerve cord and brain (22). Analysis of polytene chromosomes showed a distinct patterning, which indicates association with particular target genes (22). In analogy to $TAF_{II}170$, it is likely that, in Drosophila cell extracts, the 89B helicase/moira protein is also present in a TBP-TAF complex and that TBP is responsible for its association with chromatin. Similar to MOT1, moira is essential for viability, and this strongly suggests that inactivation of both TAF_{II}170 alleles in mice will be lethal. The moira gene was isolated as an activator of homeotic gene expression and belongs to the Trithorax group of genes (23). This heterogenous group also includes Drosophila brahma, which also belongs to the SNF2 family. Members of this family contain a DNA-stimulated (d)ATPase activity and are present in various chromatin-remodeling complexes. Destabilization of chromatin structures may explain the global activation properties of proteins like brahma (for review see ref. 19).

What are the implications of the Mot1p and moira results for TAF_{II}170? It is probable that both activation and repression by Mot1p are caused by an increased redistribution of TBP–TAF complexes over pol II promoters (26). Supporting this model is the observation that B-TFIID rapidly repartitions over different promoters in template commitment assays (7). Temporally restricted genes like homeotic genes may be particularly sensitive to an impaired mobility of TBP, and this could explain the isolation of moira as a Trithorax gene. Alternatively, B-TFIID could act as a cellular reservoir for TBP.

Transient overexpression of TBP in mammalian cells results in free TBP with a short half-life of 90 min whereas the average half-life of a TBP–TAF complex in the cells exceeds 12 h (F. C. P. Holstege and H.Th.M.T., unpublished observations). It is possible that TAF_{II}170 performs a chaperone-like function for TBP. The reservoir model does not explain the classification of TAF_{II}170 homologs as global pol II regulators. Because TBP is also essential for pol I and III transcription (1), one would expect effects of MOT1/moira mutations on these systems.

It is interesting to compare $TAF_{II}170$ of B-TFIID with $TAF_{II}250$ of the (D-)TFIID complex. Both proteins contain enzymatic activities. $TAF_{II}170$ harbors a (d)ATPase activity, and $TAF_{II}250$ has acetyltransferase and protein kinase activities (32, 33). Both can bind TBP in the absence of other proteins, resulting in reduced binding of TBP to DNA (7, 34). Two lines of evidence suggest that (D-)TFIID has gene specificity. Its TAFs interact with transcription regulators in an activation domain-specific manner (2) and TAF mutations can lead to specific cell cycle arrest phenotypes (35, 36). In contrast, the present evidence indicates that the B-TFIID complex functions in pol II transcription in a global manner.

In this discussion, we assumed that the functions of Mot1p, moira, and TAF_{II}170 are dependent on interaction with TBP. It is important to stress that part of the cellular TAF_{II}170 may not be complexed to TBP. In fact, size fractionation of yeast extracts showed that Mot1p is also present in complexes lacking TBP (20). During purification from HeLa cell extracts, we observed strict coelution of TAF_{II}170 with TBP, but small amounts of TAF_{II}170 protein may have escaped detection by our polyclonal antibodies. The availability of the TAF_{II}170 cDNA clone allows development of better immunological reagents and facilitates further investigation of its role in the global regulation of pol II transcription in mammalian cells.

We thank the Bernards brothers for the gift of the B cell cDNA library and F. van Mansfeld for the mouse cDNA library. We also thank H. Stunnenberg for the recombinant TBP vaccinia virus and the pATA-gpt plasmid. We thank D. Reinberg for sharing unpublished results and M. Collart for help with the yeast experiments and for yeast strains. We acknowledge the contributions of R. Schiphof in providing HeLa cells and of F. Holstege in the isolation of TBP antibodies. We thank H. Stunnenberg and members of our lab for discussions. We also thank U. Fiedler and M. Walhout for critical reading of this manuscript. J. W. Borst was supported by the Dutch Cancer Society. This work was also supported by the Netherlands Foundation for Chemical Research.

- 1. Sharp, P. A. (1992) Cell 68, 819-821.
- Burley, S. K. & Roeder, R. G. (1996) Annu. Rev. Biochem. 65, 769–799.
- Jacq, X., Brou, C., Lutz, Y., Davidson, I., Chambon, P. & Tora, L. (1994) Cell 79, 107–117.
- Chen, J.-L., Attardi, L. D., Verrijzer, C. P., Yokomori, K. & Tjian, R. (1994) Cell 79, 93–105.

- Verrijzer, C. P., Chen, J. L., Yokomori, K. & Tjian, R. (1995) *Cell* 81, 1115–1125.
- Bertolotti, A., Lutz, Y., Heard, D. J., Chambon, P. & Tora, L. (1996) *EMBO J.* 15, 5022–5031.
- Timmers, H. T. M. & Sharp, P. A. (1991) Genes Dev. 5, 1946–1956.
- Moqtaderi, Z., Bai, Y., Poon, D. & Weil, T. (1996) Nature (London) 383, 188–191.
- 9. Walker, S. S., Reese, J. C., Apone, L. M. & Green, M. R. (1996) *Nature (London)* 383, 185–188.
- Kim, Y. J., Bjorklund, S., Li, Y., Sayre, M. H. & Kornberg, R. D. (1994) Cell 77, 599–608.
- Timmers, H. T. M., Meyers, R. E. & Sharp, P. A. (1992) Proc. Natl. Acad. Sci. USA 89, 8140–8144.
- 12. Taggart, A. K. P., Fisher, T. S. & Pugh, B. F. (1992) Cell 71, 1015–1028.
- 13. Lobo, S. M., Tanaka, M., Sullivan, M. L. & Hernandez, N. (1992) *Cell* **71**, 1029–1040.
- 14. Teichmann, M. & Seifart, K. H. (1995) EMBO J. 14, 5974-5983.
- 15. Meyers, R. E. & Sharp, P. A. (1993) Mol. Cell. Biol. 13, 7953-7960.
- Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular Cloning (Cold Spring Harbor Lab. Press, Plainview, NY).
- Walhout, A. J. M., Gubbels, J. M., Bernards, R., van der Vliet, P. C. & Timmers, H. T. M. (1997) Nucleic Acids Res. 25, 1493–1501.
- Harlow, E. & Lane, D. (1988) *Antibodies: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- 19. Pazin, M. J. & Kadonaga, J. T. (1997) Cell 88, 737-740.
- Poon, D., Campbell, A. M., Bai, Y. & Weil, P. A. (1994) J. Biol. Chem. 269, 23135–23140.
- Davis, J. L., Kunisawa, R. & Thorner, J. (1992) Mol. Cell. Biol. 12, 1879–1892.
- Goldman-Levi, R., Miller, C., Bogoch, J. & Zak, N. B. (1996) Nucleic Acids Res. 24, 3121–3128.
- Kennison, J. A. & Tamkun, J. W. (1988) Proc. Natl. Acad. Sci. USA 85, 8136–8140.
- Auble, D. T., Wang, D., Post, K. W. & Hahn, S. (1997) Mol. Cell. Biol. 17, 4842–4851.
- Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673–4680.
- Auble, D. T., Hansen, K. E., Mueller, C. G. F., Lane, W. S., Thorner, J. & Hahn, S. (1994) *Genes Dev.* 8, 1920–1934.
- 27. Collart, M. A. (1996) Mol. Cell. Biol. 16, 6668-6676.
- Piatti, S., Tazzi, R., Pizzagalli, A., Plevani, P. & Lucchini, G. (1992) Chromosoma 102, 107–113.
- 29. Jiang, Y. W. & Stillman, D. J. (1996) Genes Dev. 10, 604-619.
- 30. Madison, J. M. & Winston, F. (1997) Mol. Cell. Biol. 17, 287-295.
- 31. Wade, P. A. & Jaehning, J. A. (1996) Mol. Cell. Biol. 16, 1641–1648.
- Mizzen, C. A., Yang, X. J., Kokubo, T., Brownell, J. E., Bannister, A. J., Owen Hughes, T., Workman, J., Wang, L., Berger, S. L., Kouzarides, T., Nakatani, Y. & Allis, C. D. (1996) *Cell* 87, 1261–1270.
- 33. Dikstein, R., Ruppert, S. & Tjian, S. (1996) Cell 84, 781-790.
- Kokubo, T., Gong, D. W., Yamashita, S., Horikoshi, M., Roeder, R. G. & Nakatani, Y. (1993) *Genes Dev.* 7, 1033–1046.
- 35. Wang, E. H. & Tjian, R. (1994) Science 263, 811-814.
- Apone, L. M., Ching-man, A. V., Reese, J. C. & Green, M. R. (1996) *Genes Dev.* 10, 2368–2380.